COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Rating of "Buy" from Analysts

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) has been given an average rating of "Buy" by the seven research firms that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.83.

CMPS has been the subject of a number of recent research reports. Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a report on Tuesday.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rosalind Advisors Inc. raised its position in COMPASS Pathways by 6.5% in the third quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company's stock worth $4,923,000 after purchasing an additional 47,423 shares in the last quarter. Propel Bio Management LLC acquired a new position in COMPASS Pathways in the third quarter worth about $504,000. Acuta Capital Partners LLC acquired a new position in COMPASS Pathways in the third quarter worth about $2,435,000. Walleye Capital LLC acquired a new position in COMPASS Pathways in the third quarter worth about $2,126,000. Finally, Sio Capital Management LLC raised its position in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock worth $5,762,000 after purchasing an additional 621,222 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

Remove Ads

COMPASS Pathways Stock Down 7.0 %

NASDAQ:CMPS traded down $0.28 during trading hours on Wednesday, hitting $3.74. 1,089,511 shares of the stock traded hands, compared to its average volume of 724,235. The firm has a 50 day moving average price of $4.05 and a 200 day moving average price of $5.17. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a fifty-two week low of $3.17 and a fifty-two week high of $11.57. The firm has a market cap of $255.89 million, a price-to-earnings ratio of -1.70 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Equities research analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.